Ulrik Spork
Chairman of the board
Board member since: 2024
Born: 1964
Holdings in Spermosens:
Ulrik Spork owns through the company Sporcon Lifescience Advisors ApS 19 338 600 shares and warrant TO6 6 445 200
Ulrik Spork has a strong background in institutional investments and has held positions as Managing Partner and Senior Partner at Novo Holdings. His responsibilities have included overseeing Principal Investments, Novo Growth Equity, and Novo Ventures. Since 2016, he has served as chairman of Danish Growth Capital II. In addition to venture investments, Ulrik also has extensive experience with SME boards in the medical technology and life science sectors and has over the last 30 years served as chairman or board member in more than 30 startup companies in jurisdictions across North America, Europe and Scandinavia.
Other ongoing significant assignments: Chairman in SoftOx Solutions AS, Innocon Medical ApS, board member in Cerebriu ApS.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Aleksander Giwercman
Board member
Board member since: 2026
Born: 1955
Holdings in Spermosens:
–
Aleksander Giwercman is Professor of Reproductive Medicine at Lund University, Department of Translational Medicine in Malmö, and Senior Consultant Physician at the Reproductive Medicine Centre, Skåne University Hospital. He heads the reproductive medicine research group in Malmö. He received his doctorate from the University of Copenhagen. His research focuses on the underlying causes of male infertility, with particular expertise in sperm DNA fragmentation, oncofertility, the impact of environmental factors on reproductive health, and the long-term effects of medical and lifestyle-related factors on fertility. He has authored or co-authored more than 500 peer-reviewed articles in journals such as The Lancet Oncology, Andrology, and Human Reproduction, and has led major international research collaborations, including ReproUnion. Professor Giwercman has previously served as a scientific advisor to Spermosens.
Other ongoing significant assignments:
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Klaas Rackebrandt
Board member
Board member since: 2026
Born: 1986
Holdings in Spermosens:
–
Klaas Rackebrandt is CEO of Scalania AG and Senior Functional Excellence Portfolio and Delivery Manager at Datwyler Healthcare. He holds a doctorate in engineering from the University of Lübeck and an MBA in Engineering Management. He is a certified lead auditor under ISO 13485:2016 and has extensive experience in M&A, corporate finance, business transformation and venture investment, with a particular focus on medtech and life science companies. Dr. Rackebrandt served as financial adviser to Spermosens in connection with the strategic investment secured in March 2025 and has been an active supporter of the company’s development.
Other ongoing significant assignments:
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Kushagr Punyani
Board member
Board member since: 2018
Born: 1991
Holdings in Spermosens:
Kushagr Punyani owns through the company Nested Bio AB 8 084 014 shares and warrant TO6 2 148 750
Kushagr Punyani is the founder of the Company and served as a CSO consultant for the company until March 2024. Kushagr holds a Licentiate degree in Engineering, specializing in microfluidic technology, from Lund University. From his studies in India, together with Professor Sudha Srivastava, Kushagr laid the foundation for the Company’s technology. He has also co-founded several companies developing new technologies in the medtech/pharmaceutical sectors.
Other ongoing significant assignments: Board member of Prolevi Bio AB and Diagonal Bio AB. Board member and CEO of Nested Bio AB.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
